Table 2.
Mortality
| Low risk (total N, % mortality) | Intermediate risk (total N, % mortality) | Entire Cohort (total N, % mortality) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Na | Number expired (%) | PE cause-specific deaths (% total) | Active cancer (% of expire) | Transitioned to hospice care (% of expired) |
Total Na | Number expired (%) | PE cause-specific deaths (% total) |
Active cancer (% of expired) | Transitioned to hospice care (% of expired) |
Total Na | Number expired (%) |
PE cause-specific deaths (% total) |
Active cancer (% of expired) |
Transitioned to hospice care (% of expired) |
||
| In-hospital | 162 | 0 | 0 | 0 | 0 | 252 |
9 (3.5%) |
1 (0.40%) |
5 (62.5%) |
7 (87.5%) |
424 |
11 (2.6%) |
3 (0.7%) |
5 (45.4%) |
7 (63.6%) |
|
| 30-Day | 162 |
7 (4.3%) |
0 |
7 (100%) |
5 (71.4%) |
252 |
22 (8.7%) |
2 (0.79%) |
16 (72.7%) |
16 (72.7%) |
424 |
31 (7.3%) |
4 (0.94%) |
23 (74.2%) |
21 (67.7%) |
|
| 3-Month | 153 |
15 (9.8%) |
0 |
14 (93.3%) |
12 (80%) |
251 |
48 (19.1%) |
2 (0.80%) |
35 (72.9%) |
34 (70.8%) |
414 |
65 (15.7%) |
4 (0.97%) |
49 (75.4%) |
46 (70.8%) |
|
| 6-Month | 153 |
26 (21.6%) |
0 |
23 (88.5%) |
21 (80.8%) |
246 |
59 (24.0%) |
4 (1.6%) |
43 (72.9%) |
40 (67.8%) |
409 |
87 (21.3%) |
6 (1.5%) |
66 (78.6%) |
61 (70.1%) |
|
aAfter subtracting those lost to follow-up